This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CombiMatrix Corporation Reports Third Quarter 2010 Financial Results

IRVINE, Calif., Nov. 10, 2010 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company with a focus on DNA-based clinical diagnostic testing services for oncology and pre-and postnatal developmental disorders, reported today that revenues for the third quarter of 2010 increased 68 percent to $1.0 million from $603,000 in the third quarter of 2009. Sequentially, from the second quarter to the third quarter of 2010, revenues increased 11 percent.

Net loss for the third quarter of 2010 was $2.2 million, or ($0.28) per share, compared to a net loss of $3.3 million or ($0.44) per share, for the same period in 2009. Net loss from continuing operations during the third quarter of 2010 was $1.9 million, or ($0.25) per share, compared to $1.8 million, or ($0.24) per share in the third quarter of 2009. The increase in the net loss from continuing operations in the third quarter of 2010 was due primarily to a derivative gain of $977,000 recognized in the third quarter of 2009 from the company's secured convertible debenture which was repaid during the first quarter of 2010.

According to Judd Jessup, who was named president and chief executive officer of CombiMatrix in August 2010, the increased revenue during the third quarter of 2010 resulted from an increase of approximately 82 percent in diagnostic testing services revenue to $924,000 from $507,000 in the prior year period, driven by increased volumes in both of the company's key areas of diagnostic testing.

For the first nine months of 2010, revenues were $2.8 million, compared to $1.9 million in the first nine months of 2009, with a net loss of $11.6 million, or ($1.53) per share in the first nine months of 2010, compared to a net loss of $14.0 million, or $(2.01) per share, in the first nine months of 2009. Net loss from continuing operations for the first nine months of 2010 was $4.5 million, or ($0.59) per share, compared to $9.2 million, or ($1.32) per share for the first nine months of 2009.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs